Bischoff Heike A, Stähelin Hannes B, Dick Walter, Akos Regula, Knecht Margrith, Salis Christian, Nebiker Matthias, Theiler Robert, Pfeifer Michael, Begerow Bettina, Lew Robert A, Conzelmann Martin
Department of Orthopaedics, University of Basel, Basel, Switzerland.
J Bone Miner Res. 2003 Feb;18(2):343-51. doi: 10.1359/jbmr.2003.18.2.343.
Specific receptors for vitamin D have been identified in human muscle tissue. Cross-sectional studies show that elderly persons with higher vitamin D serum levels have increased muscle strength and a lower number of falls. We hypothesized that vitamin D and calcium supplementation would improve musculoskeletal function and decrease falls. In a double-blind randomized controlled trial, we studied 122 elderly women (mean age, 85.3 years; range, 63-99 years) in long-stay geriatric care. Participants received 1200 mg calcium plus 800 IU cholecalciferol (Cal+D-group; n = 62) or 1200 mg calcium (Cal-group; n = 60) per day over a 12-week treatment period. The number of falls per person (0, 1, 2-5, 6-7, >7 falls) was compared between the treatment groups. In an intention to treat analysis, a Poisson regression model was used to compare falls after controlling for age, number of falls in a 6-week pretreatment period, and baseline 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D serum concentrations. Among fallers in the treatment period, crude excessive fall rate (treatment - pretreatment falls) was compared between treatment groups. Change in musculoskeletal function (summed score of knee flexor and extensor strength, grip strength, and the timed up&go test) was measured as a secondary outcome. Among subjects in the Cal+D-group, there were significant increases in median serum 25-hydroxyvitamin D (+71%) and 1,25-dihydroxyvitamin D (+8%). Before treatment, mean observed number of falls per person per week was 0.059 in the Cal+D-group and 0.056 in the Cal-group. In the 12-week treatment period, mean number of falls per person per week was 0.034 in the Cal+D-group and 0.076 in the Cal-group. After adjustment, Cal+D-treatment accounted for a 49% reduction of falls (95% CI, 14-71%; p < 0.01) based on the fall categories stated above. Among fallers of the treatment period, the crude average number of excessive falls was significantly higher in the Cal-group (p = 0.045). Musculoskeletal function improved significantly in the Cal+D-group (p = 0.0094). A single intervention with vitamin D plus calcium over a 3-month period reduced the risk of falling by 49% compared with calcium alone. Over this short-term intervention, recurrent fallers seem to benefit most by the treatment. The impact of vitamin D on falls might be explained by the observed improvement in musculoskeletal function.
在人体肌肉组织中已鉴定出维生素D的特异性受体。横断面研究表明,血清维生素D水平较高的老年人肌肉力量增强,跌倒次数减少。我们推测补充维生素D和钙会改善肌肉骨骼功能并减少跌倒。在一项双盲随机对照试验中,我们对122名长期接受老年护理的老年女性(平均年龄85.3岁;范围63 - 99岁)进行了研究。在为期12周的治疗期间,参与者每天接受1200毫克钙加800国际单位胆钙化醇(钙 + D组;n = 62)或1200毫克钙(钙组;n = 60)。比较了治疗组之间每人的跌倒次数(0次、1次、2 - 5次、6 - 7次、>7次跌倒)。在意向性分析中,使用泊松回归模型在控制年龄、6周预处理期的跌倒次数以及基线25 - 羟基维生素D和1,25 - 二羟基维生素D血清浓度后比较跌倒情况。在治疗期间的跌倒者中,比较了治疗组之间的粗超额跌倒率(治疗后 - 预处理后跌倒)。将肌肉骨骼功能的变化(膝部屈伸肌力量、握力和定时起立行走测试的总分)作为次要结果进行测量。在钙 + D组的受试者中,血清25 - 羟基维生素D中位数显著增加(+71%),1,25 - 二羟基维生素D中位数显著增加(+8%)。治疗前,钙 + D组每人每周的平均跌倒观察次数为0.059次,钙组为0.056次。在12周的治疗期内,钙 + D组每人每周的平均跌倒次数为0.034次,钙组为0.076次。调整后,根据上述跌倒类别,钙 + D治疗使跌倒风险降低了49%(95%置信区间,14 - 71%;p < 0.01)。在治疗期的跌倒者中,钙组的粗平均超额跌倒次数显著更高(p = 0.045)。钙 + D组的肌肉骨骼功能有显著改善(p = 0.0094)。与单独补钙相比,在3个月期间单次补充维生素D加钙可使跌倒风险降低49%。在这种短期干预中,反复跌倒者似乎从治疗中获益最大。维生素D对跌倒的影响可能可以通过观察到的肌肉骨骼功能改善来解释。